Display options
Cite
Ascunce RR, Berger JS, Weintraub HS, et al. The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Curr Atheroscler Rep. 2012;doi: 10.1007/s11883-012-0229-0.
Ascunce, R. R., Berger, J. S., Weintraub, H. S., & Schwartzbard, A. (2012). The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Current atherosclerosis reports, . https://doi.org/10.1007/s11883-012-0229-0
Ascunce, Rebecca Rudominer, et al. "The Role of Statin Therapy for Primary Prevention: What is the Evidence?." Current atherosclerosis reports vol. (2012). doi: https://doi.org/10.1007/s11883-012-0229-0
Ascunce RR, Berger JS, Weintraub HS, Schwartzbard A. The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Curr Atheroscler Rep. 2012 Jan 29; doi: 10.1007/s11883-012-0229-0. Epub 2012 Jan 29. PMID: 22286194.
Copy Download .nbib Format: NLM
Share it on

Curr Atheroscler Rep. 2012 Jan 29; doi: 10.1007/s11883-012-0229-0. Epub 2012 Jan 29.

The Role of Statin Therapy for Primary Prevention: What is the Evidence?.

Current atherosclerosis reports

Rebecca Rudominer Ascunce, Jeffrey S Berger, Howard S Weintraub, Arthur Schwartzbard

Affiliations

  1. Department of Medicine, Division of Cardiology, NYU Langone Medical Center, New York, USA, [email protected].

PMID: 22286194 DOI: 10.1007/s11883-012-0229-0

Abstract

Almost one third of annual worldwide mortality is attributed to cardiovascular disease (CVD), making it the leading cause of global death. Dyslipidemia is a well-established risk factor for CVD and plays a pivotal role in the pathogenesis of atherosclerosis. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and lower low-density lipoprotein cholesterol, have emerged as the most effective therapy to date against atherothrombotic CVD. Although their role in secondary prevention of CVD is undisputed, it remains a topic for debate as to how widely they should be used for primary prevention. The Framingham Risk Score and the National Cholesterol Education Program Adult Treatment Panel III guidelines are the cornerstones for the current guidelines for primary prevention statin therapy. Although these guidelines serve as help to evaluate cardiovascular risk and effectively identify many patients who will benefit from statin therapy, there is a growing population of "intermediate-risk" patients who may be undertreated. Additional noninvasive tests may complement the traditional risk scores, potentially expanding the indications for statins.

References

  1. Clin Ther. 2008 Jan;30(1):195-205 - PubMed
  2. Can J Cardiol. 2009 Oct;25(10):567-79 - PubMed
  3. Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):447-52 - PubMed
  4. N Engl J Med. 2006 Mar 23;354(12):1264-72 - PubMed
  5. N Engl J Med. 2008 Nov 20;359(21):2195-207 - PubMed
  6. Circulation. 2002 Jul 16;106(3):388-91 - PubMed
  7. Int J Clin Pharmacol Ther. 2011 May;49(5):293-6 - PubMed
  8. Circulation. 2007 Oct 16;116(16):1832-44 - PubMed
  9. Arch Intern Med. 2010 Jun 28;170(12):1024-31 - PubMed
  10. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed
  11. Lancet. 2011 Jun 25;377(9784):2181-92 - PubMed
  12. Am J Physiol Renal Physiol. 2006 Feb;290(2):F262-72 - PubMed
  13. N Engl J Med. 1995 Nov 16;333(20):1301-7 - PubMed
  14. Atherosclerosis. 2003 May;168(1):1-14 - PubMed
  15. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed
  16. N Engl J Med. 2009 Apr 2;360(14):1395-407 - PubMed
  17. JAMA. 1986 Nov 28;256(20):2823-8 - PubMed
  18. Circulation. 2003 May 27;107(20):2571-6 - PubMed
  19. Circulation. 2004 Jul 13;110(2):227-39 - PubMed
  20. N Engl J Med. 2007 Oct 11;357(15):1477-86 - PubMed
  21. Curr Atheroscler Rep. 2010 Jul;12(4):225-9 - PubMed
  22. Circulation. 2006 Dec 5;114(23):2517-27 - PubMed
  23. J Am Coll Cardiol. 2011 Apr 19;57(16):1666-75 - PubMed
  24. J Cardiovasc Comput Tomogr. 2008 Jul-Aug;2(4):209-13 - PubMed
  25. BMJ. 2009 Jun 30;338:b2376 - PubMed
  26. J Am Coll Cardiol. 2010 Mar 23;55(12):1266-1273 - PubMed
  27. Lancet. 2005 Oct 8;366(9493):1267-78 - PubMed
  28. Cardiol Clin. 2011 Feb;29(1):87-103 - PubMed
  29. Lancet. 2002 Jul 6;360(9326):7-22 - PubMed
  30. Lancet. 2002 Nov 23;360(9346):1623-30 - PubMed
  31. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007784 - PubMed
  32. JAMA. 2002 Dec 18;288(23):2998-3007 - PubMed
  33. Am J Nephrol. 2011;34(3):195-202 - PubMed
  34. Circulation. 2011 Jul 12;124(2):146-53 - PubMed
  35. Lancet. 2006 Sep 30;368(9542):1155-63 - PubMed
  36. Lancet. 2004 Aug 21-27;364(9435):685-96 - PubMed
  37. Arch Intern Med. 2007 Dec 10;167(22):2437-42 - PubMed
  38. JAMA. 1998 May 27;279(20):1615-22 - PubMed
  39. Circulation. 1998 May 12;97(18):1876-87 - PubMed
  40. N Engl J Med. 2008 Jun 19;358(25):2728-32 - PubMed
  41. Drug Des Devel Ther. 2011;5:325-80 - PubMed
  42. Circulation. 2003 Oct 28;108(17):2154-69 - PubMed
  43. J Am Coll Cardiol. 2007 May 29;49(21):2139-41 - PubMed

Publication Types